

S1 Table. Efficacy of ALK inhibitor trials in locally advanced or metastatic inflammatory myofibroblastic tumor

Corresponding author	Inclusion criteria	Study type (no. of patients)	Publication year	Drug	ORR (%) / CR (%)	DCR (%)	mPFS/1-yr PFS (%)
Mosse et al. [1]	> 12 mo to < 22 yr, ALK-positive	Phase II trial, 14 patients	2017	Crizotinib	86/36	100	Unreported
Fischer et al. [2]	≥ 15 yr, ALK-positive or ALK-negative	Phase II trial, 20 patients	2021	Crizotinib	ALK-positive: 66.7/16.7; ALK-negative: 14.3/0	ALK-positive: 100; ALK-negative: 85.7	ALK-positive: 18.0 mo/58.3; ALK-negative: 14.3 mo/57.1
Schoffski et al. [3]	≥ 12 mo to < 18 yr, ALK-positive	Phase I trial, 10 patients	2021	Ceritinib	70/0	80	Not reached/53

ALK, anaplastic lymphoma kinase; CR, complete response; DCR, disease control rate; mPFS, median progression-free survival; ORR, objective response rate; PFS, progression-free survival.

References

1. Mosse YP, Voss SD, Lim MS, Rolland D, Minard CG, Fox E, et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a Children's Oncology Group Study. *J Clin Oncol.* 2017;35:3215-21.
2. Fischer M, Moreno L, Ziegler DS, Marshall LV, Zwaan CM, Irwin MS, et al. Ceritinib in paediatric patients with anaplastic lymphoma kinase-positive malignancies: an open-label, multicentre, phase 1, dose-escalation and dose-expansion study. *Lancet Oncol.* 2021;22:1764-76.
3. Schoffski P, Kubickova M, Wozniak A, Blay JY, Strauss SJ, Stacchiotti S, et al. Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. *Eur J Cancer.* 2021;156:12-23.